Crohn's disease, also known as regional enteritis, is a type of chronic inflammatory bowel disease. While it may affect any part of the gastrointestinal tract, it most commonly affects the ileus and colon. It is thought to be an auto-immune disease, although this theory has been challenged in recent years.
This report provides the current prevalent population for Crohn’s disease across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team , several of the main symptoms and co-morbidities of Crohn’s have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for Crohn’s disease include:
• Gastritis and duodenitis
• Anaemia
• Other autoimmune diseases
• Deep vein thrombosis
• Skin problems; ulcers, blisters, swelling
• Inflammation of joints
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Able to quantify patient populations in global Crohn’s disease’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of Crohn’s disease and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on Crohn’s disease’s prevalent population.
• Identify sub-populations within Crohn’s disease which require treatment.
• Gain an understanding of the specific markets that have the largest number of Crohn’s disease patients.
'
Table of Contents
• List of Tables and Figures
• Introduction
• Cause of the Disease
• Risk Factors & Prevention
• Diagnosis of the Disease
• Variation by Geography/Ethnicity
• Disease Prognosis & Clinical Course
• Key Co-morbid Conditions /Features Associated with the Disease
• Methodology for Quantification of Patient Numbers
• Top-Line Prevalence for Crohn’s Disease
• Features of Crohn’s Disease Patients
o Behaviour of Crohn’s Disease
o Location and Status of Crohn’s disease
o Presence of Fistulae
• Associated Conditions of Crohn’s Disease
o Gastritis
o Ocular Associated Symptoms
o Associated Cell and Protein Conditions
o Dermatological Conditions
• Abbreviations and Acronyms used in the Report
• Other Black Swan Analysis Publications
• Black Swan Analysis Online Patient-Based Databases
• Patient-Based Offering
• Online Pricing Data and Platforms
• References
• Appendix
List of Tables
1. Prevalence of Crohn’s disease, total (000s)
2. Prevalence of Crohn’s disease, males (000s)
3. Prevalence of Crohn’s disease, females (000s)
4. Behaviour of Crohn’s Disease in patients, total (000s)
5. Location of Crohn’s Disease in patients, total (000s)
6. Clinical status of ileus Crohn’s Disease patients, total (000s)
7. Clinical status of ileocolonic Crohn’s Disease patients, total (000s)
8. Clinical status of colonic Crohn’s Disease patients, total (000s)
9. Fistulae in ileus Crohn’s Disease in patients, total (000s)
10. Fistulae in ileocolonic Crohn’s Disease in patients, total (000s)
11. Fistulae in colonic Crohn’s Disease in patients, total (000s)
12. Type of gastritis of Crohn’s Disease in patients, total (000s)
13. Prevalence of eye symptoms in Crohn’s Disease patients, total (000s)
14. Reported eye conditions in Crohn’s Disease patients, total (000s)
15. Elevated CRP (> 10 mg/L) in Crohn’s Disease patients, total (000s)
16. Elevated ESR (> 20 mm/hr) in Crohn’s Disease patients, total (000s)
17. Anaemia (Hct <36%) in Crohn’s Disease patients, total (000s)
18. Macrocytosis (MCV > 98fL) in Crohn’s Disease patients, total (000s)
19. Dysplasia in Crohn’s Disease patients, total (000s)
20. Oral ulcers in Crohn’s Disease patients, total (000s)
21. Erythema nodosum in Crohn’s Disease patients, total (000s)
22. Abbreviations and acronyms used in the report
23. USA Prevalence of Crohn’s disease by 5-yr age cohort, males (000s)
24. USA Prevalence of Crohn’s disease by 5-yr age cohort, females (000s)
25. France Prevalence of Crohn’s disease by 5-yr age cohort, males (000s)
26. France Prevalence of Crohn’s disease by 5-yr age cohort, females (000s)
27. Germany Prevalence of Crohn’s disease by 5-yr age cohort, males (000s)
28. Germany Prevalence of Crohn’s disease by 5-yr age cohort, females (000s)
29. Italy Prevalence of Crohn’s disease by 5-yr age cohort, males (000s)
30. Italy Prevalence of Crohn’s disease by 5-yr age cohort, females (000s)
31. Spain Prevalence of Crohn’s disease by 5-yr age cohort, males (000s)
32. Spain Prevalence of Crohn’s disease by 5-yr age cohort, females (000s)
33. United Kingdom Prevalence of Crohn’s disease by 5-yr age cohort, males (000s)
34. United Kingdom Prevalence of Crohn’s disease by 5-yr age cohort, females (000s)
35. Brazil Prevalence of Crohn’s disease by 5-yr age cohort, males (000s)
36. Brazil Prevalence of Crohn’s disease by 5-yr age cohort, females (000s)
37. Japan Prevalence of Crohn’s disease by 5-yr age cohort, males (000s)
38. Japan Prevalence of Crohn’s disease by 5-yr age cohort, females (000s)
